Takeda buys into Amylin‘s weight-loss drug portfolio – Takeda will pay $75 million upfront for medicines including Amylin’s pramlintide/metreleptin and davalintide, in the second phase of testing needed for U.S. regulatory approval, Osaka- based Takeda and San Diego-based Amylin said in a statement…more Plus, quickie update on three other anti-obesity drugs being developed by various companies.
New lupus treatment (HGS/Glaxo) looking promising on pathway to approval – Human Genome Sciences Inc said its experimental lupus drug Benlysta was successful in a second large clinical trial, paving the way for approval of the first new treatment for the disease in 50 years…more
Vertex HepC drug cures 80% – The hepatitis C cure rates of greater than 80% across all four patient groups of the study are also the highest ever recorded in any telaprevir study to date and exceed the cure rates reported in separate studies of boceprevir, a competing hepatitis C drug under development by Schering-Plough…more
Meetings. Event planning and execution, logistics, training. We can match you up with the ideal partner(s). Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Not counting on blockbusters – changes, and the future, at Sanofi-Aventis.
JUST FOR FUN